"Burning mouth syndrome"

Low level laser therapy for burning mouth syndrome MenuNO BIAS. NO MISINFORMATION. NO SPIN. JUST WHAT YOU NEED!The Dental ElfHomeAboutCategoriesPodcastsSearchLow level laser therapy for burning mouth syndrome1 Response »NOV92023Posted byDerek RichardsBurning mouth syndrome is a complex chronic orofacial pain condition. The prevalence of burning mouth syndrome has been reported to range from 0.7 emotions in patients with burning mouth syndrome (BMS).MethodsA protocol was registered on the PROSPERO database. Searches were conducted in the PubMed, Embase, Cumulative Index of Nursing and Allied Health Literature (CINAHL), the Cochrane Library, Web of Science, and Scopus databases. English language randomised controlled trials (RCTs) of LLLT (600 – 1100nm) for the treatment of BMS were considered

Analysis of pain prognosis, medication efficacy, treatment willingness and influencing factors in patients with burning mouth syndrome: a cross-sectional survey. To explore the pain prognosis, medication efficacy and treatment willingness of patients with burning mouth syndrome (BMS) and to identify the factors influencing the pain prognosis, medication efficacy and treatment willingness

Vortioxetine versus SSRI/SNRI with Pregabalin Augmentation in Treatment-Resistant Burning Mouth Syndrome: A Prospective Clinical Trial. The treatment of Burning Mouth Syndrome (BMS) represents a challenge in tailoring appropriate medication for individual patients. The augmentation of pregabalin to conventional treatment has shown promising outcomes in relieving pain and improving the quality

Efficacy and safety of photobiomodulation combined with oral cryotherapy on oral mucosa pain in patients with burning mouth syndrome: a multi-institutional, randomized, controlled trial. The prevalence of burning mouth syndrome (BMS) is approximately 8% in clinical patients; thus, BMS remains a therapeutic challenge. Photobiomodulation (PBM) and oral cryotherapy (OCT) have been evaluated

Topical gabapentin solution for the management of burning mouth syndrome: A retrospective study. The aim of this retrospective study was to evaluate the effectiveness and safety of topical gabapentin solution (250 mg/mL) for the management of burning mouth syndrome (BMS). A retrospective chart review was conducted of all patients diagnosed with BMS and managed with gabapentin 250 mg/mL solution

Efficacy of cranial electrotherapy stimulation in patients with burning mouth syndrome: a randomized, controlled, double-blind pilot study. The Burning mouth syndrome (BMS) is a chronic pain syndrome characterized by a burning sensation in the oral mucous membranes. The etiology and pathophysiology of BMS is largely unexplained. To date, there is no evidence-based treatment strategy for BMS

The improvement of pain symptoms in patients with burning mouth syndrome through combined laser and medication therapy. The etiology of Burning Mouth Syndrome (BMS) remains unclear. To explore the differences in the therapeutic efficacy of pain improvement between medication therapy and laser therapy in patients with BMS. 45 BMS patients were randomly divided into three groups: The Combination

Efficacy of Danzhixiaoyao tablets combined with methylcobalamin tablets in the treatment of burning mouth syndrome: an open-label, randomized controlled trial. This randomized controlled trial compared the efficacy and tolerability of danzhixiaoyao pills in the accurate treatment of patients with burning mouth syndrome (BMS). Collect a total of 78 patients (75 female patients and 3 male patients

Topical amitriptyline in burning mouth syndrome: A retrospective real-world evidence study. To evaluate the effectiveness, tolerability, and safety of topical amitriptyline as a potential route of administration for the management of burning mouth syndrome. Burning mouth syndrome is a complex, idiopathic, and debilitating orofacial pain disorder that impairs quality of life, with a prevalence of up to 18% in menopausal women. Available drugs to alleviate its burning sensation have inconsistent and limited efficacy. Given its physicochemical properties, excellent tolerability, and ability to target peripheral pathways, topical amitriptyline seems a promising mechanistically specific analgesic drug for burning mouth syndrome. In this retrospective cross-sectional real-world evidence study

Efficacy of 660 nm Photobiomodulation in Burning Mouth Syndrome Management: A Single-Blind Quasi-Experimental Controlled Clinical Trial. Burning mouth syndrome (BMS) is characterized by a burning sensation of the oral mucosa without any evidence of clinical signs or underlining condition. Several treatment modalities have been utilized with various results and levels of evidence. Lately

Salivary metabolome indicates a shift in tyrosine metabolism in patients with burning mouth syndrome: a prospective case-control study. The pathophysiology of primary burning mouth syndrome (BMS) remains controversial. Targeted analyses or "omics" approach of saliva provide diagnostic or pathophysiological biomarkers. This pilot study's primary objective was to explore the pathophysiology of BMS

Pain sensitivity and quality of life of patients with burning mouth syndrome: a preliminary study in a Chinese population. Burning mouth syndrome (BMS) is an oral-facial pain disorder involving the central and peripheral nervous systems, but the evidence for altered pain sensitivity remains inconclusive. The aim of this study was to investigate pain sensitivity and oral health-related quality

Oxidative stress-mediated proapoptosis signaling: A novel theory on the mechanism underlying the pathogenesis of burning mouth syndrome. Burning mouth syndrome (BMS) is a chronic oral pain disorder characterized by a generalized burning sensation in the oral mucosa without apparent medical or dental causes. Despite various hypotheses proposed to explain BMS pathogenesis, a clear understanding

Effects of self-perceived psychological stress on clinical symptoms, cortisol, and cortisol/ACTH ratio in patients with burning mouth syndrome. Psychological stress is a crucial parameter in defining the symptoms of burning mouth syndrome (BMS). We hypothesized that the level of psychological stress in patients with BMS would correlate with severity of clinical symptoms, cortisol levels

Evaluation of serum neuron specific enolase levels among patients with primary and secondary burning mouth syndrome. Burning mouth syndrome is a painful condition of the oral cavity with ambiguous pathogenesis and diagnosis. Neuron-specific enolase is increased in several conditions including peripheral neuropathy of diabetes, ophthalmopathies, spinal cord injuries and tumors. Evidence on association of burning mouth syndrome and neuron-specific enolase is limited. This study aims to evaluate neuron-specific enolase levels in primary and secondary burning mouth syndrome patients and compare the levels of neuron-specific enolase with associated conditions in secondary burning mouth syndrome. One hundred and twenty-eight patients of more than 18 years of age with no gender predilection

Burning Mouth Syndrome (BMS)-Treatment with Verbal and Written Information, B Vitamins, Probiotics, and Low-Level Laser Therapy: A Randomized Clinical Trial. The objective of this study was to determine the most effective treatment option for burning mouth syndrome. Informative treatment alone, B vitamin injections, oral cavity probiotics, and low-level laser therapy were evaluated and compared . The study included new patients diagnosed with burning mouth syndrome, who were randomly allocated into one of four treatment groups. The primary outcome was improvement in patient's quality of life as determined by a self-perceived Oral Health Impact Profile-14 (OHIP-14) quality of life questionnaire before and after therapy. The secondary outcome was determination of mucosal symptom intensity according

Interoceptive accuracy is related to the psychological mechanisms of the burning mouth syndrome: a cross-sectional study. Different perspectives are needed to understand the pathophysiology of burning mouth syndrome (BMS), including physiological and psychological standpoints. The significance of interoception in chronic pain has been suggested. However, few studies have investigated

Response to Treatment with Melatonin and Clonazepam versus Placebo in Patients with Burning Mouth Syndrome. Objective: to evaluate the efficacy of melatonin and clonazepam versus placebo in patients with burning mouth syndrome (BMS). Methods: a prospective double-blind study was carried out in patients with BMS and randomized to three groups: melatonin (1 mg once a day), clonazepam (0.5 mg/twice

Comparison of Clonazepam and Tongue Protector in the Treatment of Burning Mouth Syndrome. BMS is a chronic pain syndrome affecting the oral mucosa. It consists of experiencing a burning or dysesthetic sensation. BMS prevalence varies, with up to 15% among women. An effective treatment is still unattainable. A total of 60 patients with BMS qualified for a randomised trial, divided in two groups

Enhanced pain facilitation rather than impaired pain inhibition in burning mouth syndrome female patients. Deficient endogenous pain modulation has been implicated in the development and exacerbation of chronic orofacial pain. To date, relatively little is known regarding the function of the endogenous pain modulation in patients with burning mouth syndrome (BMS). This case-control study